Effect of recombinant human growth hormone on intestinal absorption and body composition in children with short bowel syndrome.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

This prospective study aimed to establish the effect of recombinant human growth hormone (rhGH) on intestinal function in children with short bowel syndrome (SBS).

Clinical and biological assessments were performed at baseline, at the end of the treatment period, and 12 months after the end of treatment.

Who Took Part

According to the abstract, 6 children were involved.

The age groups tagged for this paper are young children and children, both men and women.

Eight children with neonatal SBS were included.

What Was Measured

This prospective study aimed to establish the effect of recombinant human growth hormone (rhGH) on intestinal function in children with short bowel syndrome (SBS).

Clinical and biological assessments were performed at baseline, at the end of the treatment period, and 12 months after the end of treatment.

Topics PubMed links to this paper include Body Composition, Citrulline, Energy Intake, Energy Metabolism, Enteral Nutrition, Human Growth Hormone and Insulin-Like Growth Factor Binding Protein 3.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 6 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2011 (JPEN. Journal of parenteral and enteral nutrition), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.